Acute myeloid leukemia (AML) is a group of hematological malignancies with high heterogeneity.
There is an increasing need to improve the risk stratification of AML patients, including …

Rapidly proliferating leukemic progenitor cells consume substantial glucose, which may lead
to glucose insufficiency in bone marrow. We show that acute myeloid leukemia (AML) cells …

The 2-hydroxyglutarate (2-HG) has been reported to result from mutations of isocitrate
dehydrogenase 1 and 2 (IDH1 and IDH2) genes and to function as an “oncometabolite.” To …

Cancer cells are usually characterized by hyperactive glucose metabolism, which can often
lead to glucose scarcity; thus, alternative pathways to rewire cancer metabolism are required…

Acute myeloid leukemia (AML) is a life-threatening hematological disease. Novel diagnostic
and prognostic markers will be essential for new therapeutics and for significantly improving …

Lung cancer (LC) is a leading cause of cancer-related deaths worldwide. Its rapid growth
requires hyperactive catabolism of principal metabolic fuels. It is unclear whether fructose, an …

Cisplatin is an important agent in first-line chemotherapy against gastric cancer (GC). However,
consequential drug resistance limits its effectiveness for the treatment of GC. In this study…

Esophageal squamous cell carcinoma (ESCC) is a major histological subtype of esophageal
cancer with inferior prognosis. Here, we conducted comprehensive transcriptomic, …

Esophageal squamous cell carcinoma (ESCC) is a deadly malignancy with notable metabolic
reprogramming, yet the pivotal metabolic feature driving ESCC progression remains …

Fructose is an important alternative carbon source for several tumors, and GLUT5 is the
major fructose transporter which mediates most of fructose uptake in cells. So far, it is unclear …